Literature DB >> 18334220

Mechanism of activation and inhibition of the HER4/ErbB4 kinase.

Chen Qiu1, Mary K Tarrant, Sung Hee Choi, Aruna Sathyamurthy, Ron Bose, Sudeep Banjade, Ashutosh Pal, William G Bornmann, Mark A Lemmon, Philip A Cole, Daniel J Leahy.   

Abstract

HER4/ErbB4 is a ubiquitously expressed member of the EGF/ErbB family of receptor tyrosine kinases that is essential for normal development of the heart, nervous system, and mammary gland. We report here crystal structures of the ErbB4 kinase domain in active and lapatinib-inhibited forms. Active ErbB4 kinase adopts an asymmetric dimer conformation essentially identical to that observed to be important for activation of the EGF receptor/ErbB1 kinase. Mutagenesis studies of intact ErbB4 in Ba/F3 cells confirm the importance of this asymmetric dimer for activation of intact ErbB4. Lapatinib binds to an inactive form of the ErbB4 kinase in a mode equivalent to its interaction with the EGF receptor. All ErbB4 residues contacted by lapatinib are conserved in the EGF receptor and HER2/ErbB2, which lapatinib also targets. These results demonstrate that key elements of kinase activation and inhibition are conserved among ErbB family members.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334220      PMCID: PMC2858219          DOI: 10.1016/j.str.2007.12.016

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  41 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

Review 2.  Breast cancer: the upgraded role of HER-3 and HER-4.

Authors:  Michalis V Karamouzis; Filitsa A Badra; Athanasios G Papavassiliou
Journal:  Int J Biochem Cell Biol       Date:  2006-12-27       Impact factor: 5.085

3.  The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand.

Authors:  Samuel Bouyain; Patti A Longo; Shiqing Li; Kathryn M Ferguson; Daniel J Leahy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

4.  Transphosphorylation as a possible mechanism for insulin and epidermal growth factor receptor activation.

Authors:  R Lammers; E Van Obberghen; R Ballotti; J Schlessinger; A Ullrich
Journal:  J Biol Chem       Date:  1990-10-05       Impact factor: 5.157

5.  Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein.

Authors:  S L Sierke; K Cheng; H H Kim; J G Koland
Journal:  Biochem J       Date:  1997-03-15       Impact factor: 3.857

6.  Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors.

Authors:  Perry S Brignola; Karen Lackey; Sue H Kadwell; Christine Hoffman; Earnest Horne; H Luke Carter; J Darren Stuart; Kevin Blackburn; Mary B Moyer; Krystal J Alligood; Wilson B Knight; Edgar R Wood
Journal:  J Biol Chem       Date:  2001-11-05       Impact factor: 5.157

7.  Extracellular domains drive homo- but not hetero-dimerization of erbB receptors.

Authors:  K M Ferguson; P J Darling; M J Mohan; T L Macatee; M A Lemmon
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

8.  Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.

Authors:  Hyun-Soo Cho; Karen Mason; Kasra X Ramyar; Ann Marie Stanley; Sandra B Gabelli; Dan W Denney; Daniel J Leahy
Journal:  Nature       Date:  2003-02-13       Impact factor: 49.962

9.  ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface.

Authors:  Mitchell B Berger; Jeannine M Mendrola; Mark A Lemmon
Journal:  FEBS Lett       Date:  2004-07-02       Impact factor: 4.124

Review 10.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors.

Authors:  Antony W Burgess; Hyun-Soo Cho; Charles Eigenbrot; Kathryn M Ferguson; Thomas P J Garrett; Daniel J Leahy; Mark A Lemmon; Mark X Sliwkowski; Colin W Ward; Shigeyuki Yokoyama
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

View more
  82 in total

1.  Structural basis for negative cooperativity in growth factor binding to an EGF receptor.

Authors:  Diego Alvarado; Daryl E Klein; Mark A Lemmon
Journal:  Cell       Date:  2010-08-20       Impact factor: 41.582

Review 2.  Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.

Authors:  Andrea de Bartolomeis; Gianmarco Latte; Carmine Tomasetti; Felice Iasevoli
Journal:  Mol Neurobiol       Date:  2013-09-03       Impact factor: 5.590

3.  Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases.

Authors:  Andrew J Shih; Shannon E Telesco; Sung-Hee Choi; Mark A Lemmon; Ravi Radhakrishnan
Journal:  Biochem J       Date:  2011-06-01       Impact factor: 3.857

4.  The juxtamembrane region of the EGF receptor functions as an activation domain.

Authors:  Monica Red Brewer; Sung Hee Choi; Diego Alvarado; Katarina Moravcevic; Ambra Pozzi; Mark A Lemmon; Graham Carpenter
Journal:  Mol Cell       Date:  2009-06-26       Impact factor: 17.970

5.  The Nudix hydrolase CDP-chase, a CDP-choline pyrophosphatase, is an asymmetric dimer with two distinct enzymatic activities.

Authors:  Krisna C Duong-Ly; Sandra B Gabelli; Wenlian Xu; Christopher A Dunn; Andrew J Schoeffield; Maurice J Bessman; L Mario Amzel
Journal:  J Bacteriol       Date:  2011-04-29       Impact factor: 3.490

6.  Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.

Authors:  Natalia Jura; Yibing Shan; Xiaoxian Cao; David E Shaw; John Kuriyan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-09       Impact factor: 11.205

7.  Geldanamycin selectively targets the nascent form of ERBB3 for degradation.

Authors:  Candice S Gerbin; Ralf Landgraf
Journal:  Cell Stress Chaperones       Date:  2010-01-19       Impact factor: 3.667

Review 8.  ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.

Authors:  David F Stern
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

9.  In vitro enzymatic characterization of near full length EGFR in activated and inhibited states.

Authors:  Chen Qiu; Mary K Tarrant; Tatiana Boronina; Patti A Longo; Jennifer M Kavran; Robert N Cole; Philip A Cole; Daniel J Leahy
Journal:  Biochemistry       Date:  2009-07-21       Impact factor: 3.162

10.  Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.

Authors:  Ying-Xin Fan; Lily Wong; Michael P Marino; Wu Ou; Yi Shen; Wen Jin Wu; Kwok-Kin Wong; Jakob Reiser; Gibbes R Johnson
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.